Mustang Bio, Inc. (MBIO)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Mustang Bio, Inc. (MBIO) is a publicly traded company in the Healthcare sector. Trailing PE -0.80. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Valuation
| P/E (TTM) | -0.80× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | 0.32× |
| P/FCF (TTM) | -0.54× |
| EV / EBITDA | 4.20× |
| EV / Sales | 0.00× |
| Earnings Yield | -125.10% |
| Free Cash Flow Yield | -186.08% |
Fundamentals
| Enterprise Value | -$12.73M |
|---|---|
| Net Income (TTM) | -$3.03M |
| Free Cash Flow (TTM) | -$4.51M |
| Net Debt | -$15.15M |
| Working Capital | $7.70M |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -34.23% |
| Return on Invested Capital | -45.77% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap